Table 1.
Baseline characteristics of the study population.
| n = 54 | |
|---|---|
| Age at baseline (years), median (IQR) | 75.0 (69.0–79.0) |
| Age of onset (years), median (IQR) | 73.5 (68.0–77.0) |
| Gender | |
| Males | 38 (70.4) |
| Females | 16 (29.6) |
| Ever-smoker | 31 (57.4) |
| Previous coexisting disease | |
| GERD | 16 (29.6) |
| COPD | 5 (9.3) |
| Cancer | 7 (13.0) |
| Concomitant medication | |
| OCS | 17 (31.5) |
| Hydroxychloroquine | 0 (0.0) |
| Azathioprine | 1 (1.9) |
| Methotrexate | 0 (0.0) |
| Mycophenolate mofetil | 2 (3.7) |
| Rituximab | 0 (0.0) |
| Tocilizumab | 0 (0.0) |
| PPI | 35 (64.8) |
| HRCT pattern | |
| UIP | 38 (70.4) |
| NSIP | 9 (16.7) |
Data are presented as No. (%), unless otherwise stated. IQR: interquartile range; GERD: gastroesophageal reflux disease; COPD: chronic obstructive pulmonary disease; OCS: oral corticosteroids; PPI: proton pump inhibitors; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia; and NSIP: non-specific interstitial pneumonia.